Unither Pharmaceuticals has initiated the acquisition of Nanjing Ruinian Best Pharmaceutical Co. Ltd, a Chinese pharmaceutical company.

With this acquisition, Unither is accelerating the development of its business in China, the second largest market in the world, and complementing the worldwide Unither industrial footprint in Europe, the U.S. and Brazil.

“We are delighted to welcome this company into our group. Nanjing Ruinian Best will allow us to speed up our development and strengthen our activities in China, in line with our strategy to manufacture drugs closer to our customers” said Eric Goupil, group president of Unither. 

The acquisition will allow Unither to support both Chinese and international pharmaceutical customers active in the ophthalmology and respiratory markets in China, and to offer them expertise in drug formulation and the manufacturing of sterile preservative-free single dose drugs.